Trade Insulet Corporation - PODD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.32 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 259.33 |
| Open | 259.21 |
| 1-Year Change | 55.1% |
| Day's Range | 258.77 - 261.79 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 259.33 | 9.62 | 3.85% | 249.71 | 261.27 | 249.71 |
| Apr 23, 2025 | 246.28 | 0.15 | 0.06% | 246.13 | 255.68 | 244.97 |
| Apr 22, 2025 | 243.75 | 3.70 | 1.54% | 240.05 | 246.29 | 237.95 |
| Apr 21, 2025 | 238.51 | -2.02 | -0.84% | 240.53 | 243.82 | 237.24 |
| Apr 17, 2025 | 246.76 | 3.81 | 1.57% | 242.95 | 248.56 | 233.82 |
| Apr 16, 2025 | 250.63 | -1.82 | -0.72% | 252.45 | 256.10 | 246.97 |
| Apr 15, 2025 | 256.21 | 3.56 | 1.41% | 252.65 | 256.95 | 252.62 |
| Apr 14, 2025 | 255.37 | 0.50 | 0.20% | 254.87 | 257.12 | 252.05 |
| Apr 11, 2025 | 253.71 | 1.76 | 0.70% | 251.95 | 254.97 | 245.95 |
| Apr 10, 2025 | 251.36 | -10.59 | -4.04% | 261.95 | 261.95 | 245.54 |
| Apr 9, 2025 | 264.58 | 21.63 | 8.90% | 242.95 | 265.80 | 241.95 |
| Apr 8, 2025 | 247.00 | -13.99 | -5.36% | 260.99 | 264.26 | 244.41 |
| Apr 7, 2025 | 256.18 | 18.27 | 7.68% | 237.91 | 260.58 | 236.65 |
| Apr 4, 2025 | 245.22 | -4.73 | -1.89% | 249.95 | 250.04 | 236.77 |
| Apr 3, 2025 | 256.78 | 1.83 | 0.72% | 254.95 | 258.00 | 249.08 |
| Apr 2, 2025 | 269.09 | 9.08 | 3.49% | 260.01 | 270.11 | 259.94 |
| Apr 1, 2025 | 263.14 | 7.29 | 2.85% | 255.85 | 264.43 | 255.85 |
| Mar 31, 2025 | 262.34 | 5.71 | 2.22% | 256.63 | 263.11 | 254.61 |
| Mar 28, 2025 | 258.57 | 0.33 | 0.13% | 258.24 | 260.98 | 255.72 |
| Mar 27, 2025 | 260.21 | -1.24 | -0.47% | 261.45 | 267.74 | 259.99 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Insulet Corporation Company profile
About Insulet Corporation
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Insulet Corporation revenues increased 21% to $1.1B. Net income increased from $6.8M to $16.8M. Revenues reflect Omnipod System segment increase of 24% to $651.5M, International Omnipod segment increase of 17% to $359.9M, United States segment increase of 24% to $738.9M, All Other segment increase of 17% to $359.9M. Net income benefited from IE on Capital Financing decrease of 13% to $36.7M (expense).
Equity composition
Common Stock, $.001 Par, 03/12, 100M auth., 45,670,320 issd. Insiders own 0.45%. IPO: 5/07, 7.7M shs.@ $15 per share by JPMorgan, Merrill Lynch & Co., Thomas Weisel Partners LLC and Leerink Swann & Company. PO:11/07, 4.9M shs. @ $23.25 per share by JP Morgan and Merrill Lynch.
| Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Nagog Park
ACTON
MASSACHUSETTS 01720-3440
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com